Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Campaign to Increase Compliance with Take-Home Colorectal Screening Test

By HospiMedica staff writers
Posted on 11 Apr 2008
A novel campaign has been launched help increase compliance with take-home colorectal screening tests. More...
The campaign aims to break down barriers to compliance with fecal occult blood tests and increase screening with convenient take-home screening tools. The goal of the new campaign is to have five million people complete their annual testing over the next five years.

In the United States, nearly 60 % of women have an annual Pap test (for cervical cancer) and as many as 79 % of men receive prostate-specific antigen (PSA) screening every year for prostate cancer. In one randomized clinical study, only 31 % of patients (n = 1818) completed an at-home colorectal screening test. Despite the availability of these convenient and effective diagnostic tests, nearly 150,000 men and women in the United States will be diagnosed with colorectal cancer this year, and one-third of these patients will ultimately succumb to the disease. When found early and treated, the five-year relative survival rate for colon cancer is 90%, but less than 40% of colorectal cancers are found early.

Fecal occult blood tests (FOBTs), including the newer fecal immunochemical tests (FITs), detect blood in the stool that might indicate colorectal cancer or other lower gastrointestinal diseases. These screening tests help identify individuals that are candidates for colonoscopy, even if they do not have overt symptoms of colorectal cancer. This may mean the disease is in its early, more treatable stages, or that they may have precancerous polyps that can be removed during colonoscopy.

Quest Diagnostics (Madison, NJ, USA) is launching the campaign at the end of Cancer Awareness Month "because we want people to remember that this disease strikes every day of every month,” said Stephen C. Suffin, M.D., the company's clinical pathologist and interim chief laboratory officer. "Our Challenge is designed to encourage people 50 and over and those at risk to complete annual screening with American Cancer Society [ACS] recommended tests, such as the FDA-[U.S. Food and Drug Administration]-approved, InSure FIT test and its painless, noninvasive Blue-Brush Method.”

The Challenge urges individuals to talk to their healthcare providers about annual colorectal cancer screening using the InSure FIT take-home test, developed by Quest, and in turn, to challenge friends and family members to "have the guts” to get screened, too. Challenge participants can also send an attention-grabbing "Happy, Healthy Colon” e-card to friends and relatives as a reminder to be screened annually. Medical professionals can access the latest scientific data on InSure FIT, up-to-date colorectal cancer screening guidelines and resources, and patient education materials that can help guide discussions with their patients about colorectal cancer screening.

Quest Diagnostics is a provider of diagnostic testing, information, and services that patients and doctors need to make better healthcare decisions. The company offers access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its medical and scientific staff.


Related Links:
Quest Diagnostics

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Immunofluorescence Analyzer
IFA System
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.